TSHA

3.7201.33%
SN

Sukumar Nagendran

President, Head of Research & Development and Director

Dr. Sukumar Nagendran, M.D., also known as Suku, has been President and Head of Research and Development at Taysha Gene Therapies, Inc. since December 2022 and has been its Director since July 2020. Dr. Nagendran was President, R&D and Chief Medical Officer of Jaguar Gene Therapy, LLC from February 2020 to December 2022. Dr. Nagendran has been Independent Director of Project Healthy Minds since June 2020; Member Board Of Directors of RTW Investments SPAC since May 2019; Member Board Of Directors of Neurogene, Inc. since February 2019 and Board Member of Saliogen since September 2020. He has been an Independent Director of Solid Biosciences Inc., since September 13, 2018. He serves as Director of SalioGen Therapeutics, Inc. He has been Special Advisor of Chardan since December 2018 and Advisor of Encoded Therapeutics since October 2018. Dr. Nagendran served as the Chief Medical Officer and Senior Vice President of AveXis, Inc. since September 2015 until July 2018. Dr. Nagendran was responsible for overseeing and driving all clinical development and medical affairs strategies and efforts for AveXis and its pipeline. He served as Vice President/Head of Global Medical Affairs at Quest Diagnostics Inc. from March 2013 to September 2015. He has held key leadership positions across multiple medical functions to drive support for many innovative products, including clinical trials/operations, field medical, medical product team, national and regional payer efforts, publications, advocacy and genetic counseling activities/oversight. He was instrumental in building the medical affairs function at Quest Diagnostics, the largest lab/diagnostics provider in the world. He had been a Director of Health Sciences Acquisitions Corporation since May 14, 2019. Dr. Nagendran is a Mayo Alumni Laureate and founding Member of the Robert Wood Johnson Legacy Society. He is also the sponsor for the Fonseca-Nagendran Scholar award at the American Diabetes Association to enhance research in minority populations. He served as Vice President and Head of Medical Affairs at Reata Pharmaceuticals from October 2012 to February 2013. Prior to that, he was therapeutic-area Head for new product development, medical affairs, clinical operations and biometrics, in which he oversaw several therapeutic areas, including oncology, cardiovascular disease and diabetes, for Daiichi Sankyo. He has held other senior positions related to clinical development and medical affairs for Pfizer as Director/Team Leader- US Diabetes and Metabolism from January 2001 to January 2007 and Novartis as Lead for CVM Med Affairs/Med Director from February 2007 to February 2008. He worked at Diabetes and Internal Medicine as Consultant Physician from June 1997 to December 2000. He also has significant clinical practice expertise. In his career, Dr. Nagendran practiced in a large internal-medicine physician group and was a staff physician at three hospitals in Phoenix, Arizona. He served as Director at Immunovant, Inc. until December 2019. Dr. Nagendran research on cardiovascular disease, diabetes, oncology, pulmonary medicine and other areas of medicine has been published in a number of peer-reviewed publications, including Endocrine Practice, Current Medical Research & Opinion and Journal of Clinical Lipidology. He serves as a Member of Advisory Board of Medocity, Inc. and has been its Board Member since June 2019. He serves as a Member of Lab Advisory Board of Prognos Health Inc. (formerly known as Medivo Inc.) and an Advisor of Brandix I3. He completed his internal medicine training at The Mayo Clinic in Rochester, Minnesota from 1994 to 1997 and was inducted into the prestigious Mayo Alumni Laureate Group. Dr. Nagendran holds Mini MBA Program, BioPharma Innovation from Rutgers, The State University of New Jersey - Rutgers Business School from 2012 to 2012; Certification, Executive Education For Leaders from University of Pennsylvania - The Wharton School from 2010 to 2010; N/A, Strategies for Enhancing Executive Influence from Center For Management Research from 2008 to 2008 and Residency, Internal Medicine from Mayo Graduate School from 1994 to 1997. He received his M.D. at Rutgers Medical School. Dr. Nagendran earned a bachelor's degree in biochemistry from Rutgers University and earned his doctorate in medicine from UMDNJ-Robert Wood Johnson Medical School in New Jersey, where he was given the Robert Wood Johnson Alumni award for outstanding medical student.

Positions